201 related articles for article (PubMed ID: 16417696)
1. A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003.
Morrell S; Taylor R; Wain G
J Med Screen; 2005; 12(4):190-6. PubMed ID: 16417696
[TBL] [Abstract][Full Text] [Related]
2. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
3. Risk of invasive cervical cancer after Pap smears: the protective effect of multiple negatives.
Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
J Med Screen; 2005; 12(1):7-11. PubMed ID: 15814014
[TBL] [Abstract][Full Text] [Related]
4. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women.
Yang B; Morrell S; Zuo Y; Roder D; Tracey E; Jelfs P
Cancer Causes Control; 2008 Aug; 19(6):569-76. PubMed ID: 18286380
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
6. Screening for cervical disease in mature women: strategies for improvement.
Colgan TJ; Clarke A; Hakh N; Seidenfeld A
Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
[TBL] [Abstract][Full Text] [Related]
7. Risk of invasive cervical cancer in relation to management of abnormal Pap smear results.
Silfverdal L; Kemetli L; Andrae B; Sparén P; Ryd W; Dillner J; Strander B; Törnberg S
Am J Obstet Gynecol; 2009 Aug; 201(2):188.e1-7. PubMed ID: 19560117
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
Howell LP; Gurusinghe S; Tabnak F; Sciortino S
Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
[TBL] [Abstract][Full Text] [Related]
9. Risk of invasive cervical cancer after three consecutive negative Pap smears.
Coldman A; Phillips N; Kan L; Matisic J; Benedet L; Towers L
J Med Screen; 2003; 10(4):196-200. PubMed ID: 14738657
[TBL] [Abstract][Full Text] [Related]
10. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for cervical neoplasia in Denmark.
Kjaer SK
APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
13. Cervix cancer screening in Croatia within the European Cervical Cancer Prevention Week.
Skopljanac-Macina L; Mahovlić V; Ovanin-Rakić A; Barisić A; Rajhvajn S; Juric D; Babić D; Corusić A; Oresković S
Coll Antropol; 2010 Jun; 34(2):613-7. PubMed ID: 20698138
[TBL] [Abstract][Full Text] [Related]
14. Laboratory performance measures: evidence against low-risk women explaining low detection rates of high-grade abnormalities.
Mitchell HS
Cytopathology; 2005 Apr; 16(2):77-81. PubMed ID: 15787649
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up.
Branca M; Garbuglia AR; Benedetto A; Cappiello T; Leoncini L; Migliore G; Agarossi A; Syrjänen K;
Int J STD AIDS; 2003 Jun; 14(6):417-25. PubMed ID: 12816671
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
17. Cervical cytology in vulnerable pregnant women.
Loomis DM; Pastore PA; Rejman K; Gutierrez KL; Bethea B
J Am Acad Nurse Pract; 2009 May; 21(5):287-94. PubMed ID: 19432913
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cervical cancer screening program at a rural community of South Africa.
Hoque M; Hoque E; Kader SB
East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
20. Pap smear screening in a health maintenance organization: 1986-1990.
Rolnick S; LaFerla JJ; Wehrle D; Trygstad E; Okagaki T
Prev Med; 1996; 25(2):156-61. PubMed ID: 8860280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
